NASDAQ · GLUE
Healthcare · Biotechnology
$10.50
Down-$0.76 (-6.75%)
Updated Oct 3, 2026, 11:39 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · GLUE
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
GLUE closed at $10.50 after 20 trading sessions, down 24.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $11.40 | $11.40 | $10.32 | $10.50 | 2.21M |
| Oct 1, 2026 | $12.15 | $12.2594 | $11.07 | $11.26 | 2.87M |
| Sep 30, 2026 | $11.85 | $12.15 | $11.65 | $11.93 | 913.96K |
| Sep 29, 2026 | $11.68 | $12.17 | $11.56 | $11.74 | 545.07K |
| Sep 28, 2026 | $11.69 | $11.98 | $11.50 | $11.71 | 772.66K |
| Sep 25, 2026 | $11.75 | $11.89 | $11.615 | $11.77 | 802.14K |
| Sep 24, 2026 | $11.93 | $11.995 | $11.415 | $11.72 | 1.14M |
| Sep 23, 2026 | $12.60 | $12.606 | $11.70 | $11.89 | 1.18M |
| Sep 22, 2026 | $12.35 | $12.73 | $12.21 | $12.60 | 1.21M |
| Sep 21, 2026 | $12.20 | $12.315 | $12.06 | $12.26 | 1.13M |
| Sep 18, 2026 | $12.57 | $12.641 | $12.02 | $12.13 | 1.6M |
| Sep 17, 2026 | $12.84 | $13.02 | $12.43 | $12.60 | 1.39M |
| Sep 16, 2026 | $12.94 | $13.01 | $12.59 | $12.65 | 1.5M |
| Sep 15, 2026 | $13.84 | $13.88 | $12.87 | $12.99 | 1.27M |
| Sep 14, 2026 | $14.35 | $14.38 | $13.38 | $13.90 | 1.79M |
| Sep 11, 2026 | $14.235 | $14.74 | $13.88 | $14.07 | 1.17M |
| Sep 10, 2026 | $14.21 | $14.34 | $13.83 | $14.32 | 1.06M |
| Sep 9, 2026 | $14.28 | $14.87 | $14.13 | $14.26 | 1.15M |
| Sep 8, 2026 | $13.55 | $14.29 | $13.44 | $14.27 | 1.2M |
| Sep 4, 2026 | $14.12 | $14.31 | $13.79 | $13.84 | 804.59K |
The latest Smart Investors Daily articles mentioning GLUE.
Company
Market Activity
Research & News
GLUE research
Company profile and research snapshot.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 1, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 9, 2026 | Wedbush | Outperform | — |
| Aug 25, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | Guggenheim | Buy | — |
| Aug 7, 2026 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 13, 2026
On September 8, Monte Rosa Therapeutics (NASDAQ:GLUE) announced that Novartis (NYSE:NVS), its partner on a VAV1-targeted drug, had dosed the first patient in a Phase 2 trial of MRT-6160 (DDY391) for people with Sjögren’s disease. That single clinical checkpoint triggers a $50 million payment to Monte Rosa and marks just the first step in a […]
Benzinga · Sep 9, 2026
Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $27 price target.
Yahoo · Sep 8, 2026
All three major US stock indexes fell in late-morning trading Tuesday as oil prices climbed and inve
Yahoo · Sep 8, 2026
Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to receive milestone payment based on first patient visit of Phase 2 clinical study Additional studies expected to evaluate the potential of MRT-6160 (DDY391) across immune-mediated diseases; Monte Rosa eligible for additional Phase 2 study initiation milestones BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE)
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLUE.
